Clinical Trial Update: BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating modulation of the recMAGE-A3 ASCI vaccine with AS15 adjuvant using BCG in non-muscle invasive bladder cancer; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• AS15 (AS15 adjuvant)
• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• recMAGE-A3 ASCI (recMAGE-A3)

Snippet

Sponsor: Patrice Jichlinski | Conditions: Bladder Cancer | Phase 1 | Status: COMPLETED